Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Postibrutinib outcomes in patients with mantle cell lymphoma.
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. Martin P, et al. Among authors: maddocks k. Blood. 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13. Blood. 2016. PMID: 26764355 Free article.
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Croce CM, Byrd JC, Johnson AJ. Hertlein E, et al. Blood. 2010 Jul 8;116(1):45-53. doi: 10.1182/blood-2010-01-263756. Epub 2010 Mar 29. Blood. 2010. PMID: 20351313 Free PMC article.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Dubovsky JA, et al. Among authors: maddocks k. Blood. 2013 Oct 10;122(15):2539-49. doi: 10.1182/blood-2013-06-507947. Epub 2013 Jul 25. Blood. 2013. PMID: 23886836 Free PMC article. Clinical Trial.
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. Woyach JA, et al. Among authors: maddocks k. Blood. 2014 Mar 20;123(12):1810-7. doi: 10.1182/blood-2013-09-527853. Epub 2014 Jan 10. Blood. 2014. PMID: 24415539 Free PMC article.
Ibrutinib in B-cell Lymphomas.
Maddocks K, Blum KA. Maddocks K, et al. Curr Treat Options Oncol. 2014 Jun;15(2):226-37. doi: 10.1007/s11864-014-0274-8. Curr Treat Options Oncol. 2014. PMID: 24481980 Review.
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KA. Cohen JB, et al. Cancer. 2014 Jun 1;120(11):1677-85. doi: 10.1002/cncr.28642. Epub 2014 Feb 27. Cancer. 2014. PMID: 24578014 Free PMC article.
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.
El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FT, Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC. El-Gamal D, et al. Among authors: maddocks k. Blood. 2014 Aug 28;124(9):1481-91. doi: 10.1182/blood-2014-05-574830. Epub 2014 Jul 7. Blood. 2014. PMID: 25001469 Free PMC article.
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA. Maddocks K, et al. Am J Hematol. 2015 Apr;90(4):327-33. doi: 10.1002/ajh.23946. Epub 2015 Feb 25. Am J Hematol. 2015. PMID: 25639448 Free PMC article. Clinical Trial.
Treatment strategies in mantle cell lymphoma.
Maddocks K, Blum KA. Maddocks K, et al. Cancer Treat Res. 2015;165:251-70. doi: 10.1007/978-3-319-13150-4_10. Cancer Treat Res. 2015. PMID: 25655613 Review.
132 results